A randomized, double-blind trial of filgrastim (granulocyte colony- stimulating factor) versus placebo following allogeneic blood stem cell transplantation

Blood

Volumn 96, Issue 1, 2000, Pages 80-85

  Bishop, Michael R ^a   Tarantolo, Stefano R ^b   Geller, Robert B ^b   Lynch, James C ^b   Bierman, Philip J ^b   Pavletic, Z Steven ^b   Vose, Julie M ^b   Kruse, Susan ^b   Dix, Suzanne P ^b   Morris, Mary E ^b   Armitage, James O ^b   Kessinger, Anne ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MESNA; METHOTREXATE; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0034235308     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.1.80.013k35_80_85     Document Type: Article

References (36)

1. Rizzo JD. New summary slides show current trends in BMT. ABMTR Newsletter. 1998;5:4.
2. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood. 1995;85:1655.
3. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995;85:1659.
4. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 1995;85:1666.
5. Goldman J. Peripheral blood stem cells for allografting [editorial]. Blood. 1995;6:1413.
6. Schmitz N, Bacigalupo A, Labopin M, et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996;95:715.
7. Russell JA, Brown C, Bowen T, et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant. 1996;17:703.
8. Rosenfeld C, Collins R, Pineiro L, Agura E, Nemunaitis J. Allogeneic blood cell transplantation without posttransplant colony-stimulating factors in patients with hematopoietic neoplasm: a phase II study. J Clin Oncol. 1996;14:1314.
9. Pavletic ZS, Bishop MR, Tarantolo SR, et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol. 1997;15:1608.
10. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating hemopoietic progenitor cell component in man. Lancet. 1988;1:1194.
11. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640.
12. Matsunaga T, Sakamaki S, Kohgo Y, Ohi S. Hirayama Y, Niftsu Y. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant. 1993;11:103.
13. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood. 1995;85:275.
14. Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood. 1993;82:1981.
15. Bishop MR, Tarantolo SR, Jackson JD, et al. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. J Clin Oncol. 1997;15:1601.
16. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol. 1994;87:825.
17. Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996;88:3223.
18. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773.
19. Nemunaitis J, Buckner CD, Appelbaum FR, et al. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood. 1991;77:2065.
20. Schriber JR, Chao NJ, Long GD, et al. Granulocyte-colony stimulating factor after allogeneic transplantation. Blood. 1994;84:1680.
21. Nemunaitis J, Anasetti C, Bianco JA, Hansen J, Singer JW. rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis. Leuk Lymphoma. 1993;10:177.
22. Spitzer G, Adkins DR, Spencer V. et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol. 1994;12:661.
23. Martin-Algarra S, Bishop MR, Tarantolo S, et al. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs-host disease prophylaxis. Exp Hematol. 1995; 23:1503.
24. Yau JC, Dimopoulos MA, Huan SD, et al. An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone Am J Hematol. 1991;38:288.
25. Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica. 1999; 84:71.
26. Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998;92:2725.
27. Kawano Y, Takaue Y, Mimaya J, et al, for The Japanese Study Group of PBSCT. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. Blood 1998;92:4040.
28. Ojeda E, Garcia-Bustos J, Agaudo MJ, et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children [letter]? Blood. 1999;93:3565.
29. Ciernik IF, Schanz U, Gmür J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant. 1999;24:147.
30. Miflin G, Russell NH, Hutchinson RM, et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant. 1997;19:9.
31. Przepiorka D, Anderlini P, Ippoliti C, et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marow Transplant. 1997;19:455.
32. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:995.
33. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422.
34. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood. 1997;90:453.
35. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood. 1994;84:3540.
36. Tarantolo SR, Bishop MR, Lynch JC, et al. Effect of G-CSF mobilization on type 1 and type 2 T-cells and correlation to acute graft-versus-host disease. Blood. 1998;92(suppl 1):722a.